DUBLIN--(BUSINESS WIRE)--Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near vision restoration announced today the appointment of Marie Cha as Director of Direct Response Marketing. Ms. Cha brings extensive experience in consumer marketing, with a strong focus on digital platforms. Ms. Cha will be responsible for overseeing the development and expansion of direct response marketing for the Presbia Flexivue Microlens™, a proprietary optical lens implant for treating presbyopia, or problems reading.
“Marie’s proven track record in digital and direct response marketing will accelerate awareness and consumer adoption of Presbia’s innovative solution for correcting common age-related near vision loss, and drive the growth of our business in both current and future commercial markets,” said Todd Cooper, President and CEO of Presbia.
Ms. Cha’s career includes global marketing experience, most recently serving as Director of Marketing for Xoom Corporation, a leading digital payments business where she led growth initiatives across all digital platforms. Prior to that time she served in a senior marketing role for DirecTV, Inc. spearheading the development and execution of digital and direct response marketing for its international segments. Earlier in her career she was an account manager for Ten Communication and also held various sales and marketing positions for IBM Korea.
The Presbia Flexivue Microlens™ has received regulatory approval from the Korean Ministry of Food and Drug Safety as well as received CE certification, meeting European Union consumer safety, health, and environmental requirements for products sold within the European Economic Area. Currently Presbia is conducting the final stage enrollment of the U.S. Food and Drug Administration (FDA) pivotal study for its Microlens™. The study is progressing on schedule moving toward a timely submission to obtain FDA approval.
Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.